Administration of 9 THC to rats has been reported to lessen their power to avoid disease with the herpes simplex virus 2 and the bacterial agent Listeria monocytogenes. An internally checked prognostic index confirmed a predicted gain of 10% in 5 year survival owing to the addition of GO in approximately 70-90 of patients. 26 In AML16, over 1100 older patients were randomized to enzalutamide intensive chemotherapy with either DNR/Ara C or DNR/Clofarabine with or without just one dose CONTINUE day 1, followed, or not, by a third period of treatment followed by azacitidine preservation. Preliminary results presented at the American Society of Hematology Annual Meeting in 2011 showed no significant differences in CR rate or toxicities. There clearly was a significant reduction in the rate of relapse and significant progress in most patients overall survival at 24 months. The power was lower in patients with secondary AML or bad risk cytogenetics. 27 The plenary session at the 2011 ASH Annual Meeting highlighted initial results from the ALFA 0701 trial. Castaigne, et al presented data from 271 patients with newly diagnosed AML, aged 50 C70. Patients were randomized to induction chemotherapy with 7 3 with or without GO at 3 mg/m2 on days 1, 4 and 7. Patients Organism in CR could continue to an extra 2 courses of consolidation treatment with or without GO according to initial randomization. There is no significant difference in rates of CR, induction death or primary refractory infection. Important changes were observed in the in 2 year event free survival and infection free survival between the group and the control group receiving GO. Subgroup analysis showed the EFS benefit persisted in most age brackets, but not in individuals with poor risk cytogenetics. Within the entire cohort, over all survival was longer within the GO arm than get a grip on, although this gain was non significant when cytogenetics were considered. Continuous thrombocytopenia and veno occlusive illness were noticed in the GO arm. Also presented at the meeting were initial results from the GOELAMS AML 2006 IR research. This Phase III trial randomized 238 individuals ages 18 to 60 with advanced cytogenetics to induction chemotherapy with or without GO, accompanied by consolidation chemotherapy and/or autologous or allogeneic purchase Letrozole stem-cell transplant. There were no significant differences in CR fee or early death. An increased incidence of veno occlusive infection and level 3/4 hepatic toxicities was observed in those receiving GO. Function free and over all survival at three years were not statistically different between those getting GO or not. In the subset of patients who did obtain an allogeneic transplant, EFS was considerably higher in those patients receiving GO, while there was no difference in OS at 3 years. In the US, SWOG performed a multicenter, randomized Phase III trial of 7 3 with or without the addition of GO in adults ages 18 C60 with untreated AML.